| 1 |
34449248 | A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. | 2022 Jan 6 |
3 |
| 2 |
34866168 | Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment. | 2022 Apr |
3 |
| 3 |
35179323 | Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. | 2022 Mar 24 |
1 |
| 4 |
35184345 | A case of skin rash during oral administration of a novel androgen receptor inhibitor, darolutamide. | 2022 Jul |
1 |
| 5 |
35201849 | A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide. | 2022 Feb |
1 |
| 6 |
35343943 | Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide as the first androgen receptor inhibitor in a fit, older man. | 2022 Jan |
1 |
| 7 |
35390118 | Targeting the androgen receptor signaling pathway in advanced prostate cancer. | 2022 Apr 7 |
2 |
| 8 |
35490582 | Development of novel androgen receptor antagonists based on the structure of darolutamide. | 2022 Jul |
3 |
| 9 |
35553247 | Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management. | 2022 May 13 |
1 |
| 10 |
35579577 | Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. | 2022 May |
1 |
| 11 |
32881669 | Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer. | 2021 |
9 |
| 12 |
32958445 | Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. | 2021 Jan |
1 |
| 13 |
33135506 | An up-to-date evaluation of darolutamide for the treatment of prostate cancer. | 2021 Mar |
1 |
| 14 |
33140306 | Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer. | 2021 Mar |
1 |
| 15 |
33785516 | Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans. | 2021 Jun |
1 |
| 16 |
34128827 | Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer. | 2021 Jul 15 |
1 |
| 17 |
34208290 | Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients. | 2021 Jun 11 |
2 |
| 18 |
34362254 | Current treatment of non-metastatic castration-refractory prostate cancer. | 2021 Spring |
1 |
| 19 |
34526701 | Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. | 2021 Dec |
1 |
| 20 |
34884545 | Delineating the Molecular Events Underlying Development of Prostate Cancer Variants with Neuroendocrine/Small Cell Carcinoma Characteristics. | 2021 Nov 25 |
1 |
| 21 |
31844181 | A review of prostate cancer treatment impact on the CNS and cognitive function. | 2020 Jun |
1 |
| 22 |
32333502 | Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation. | 2020 Sep |
7 |
| 23 |
32456317 | Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer. | 2020 May 24 |
1 |
| 24 |
32549073 | Clinical and Surgical Assistance in Prostate Cancer during the COVID-19 Pandemic: Implementation of assistance protocols. | 2020 Jul |
1 |
| 25 |
32562083 | Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells. | 2020 Aug |
1 |
| 26 |
32765070 | Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer. | 2020 |
2 |
| 27 |
32823970 | Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies. | 2020 Aug 14 |
2 |
| 28 |
33237495 | Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer. | 2020 Dec |
4 |
| 29 |
30115959 | Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies. | 2019 Mar |
1 |
| 30 |
30824428 | Darolutamide Slows Metastasis in Prostate Cancer. | 2019 Apr |
1 |
| 31 |
30828788 | Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models. | 2019 Sep 1 |
8 |
| 32 |
31437779 | Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants. | 2019 Nov 15 |
2 |
| 33 |
31471641 | [A new androgen receptor antagonist : Darolutamide for patients with non-metastatic castration-resistant prostate cancer]. | 2019 Oct |
1 |
| 34 |
31571146 | Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. | 2019 Dec |
2 |
| 35 |
31605368 | Darolutamide: First Approval. | 2019 Nov |
2 |
| 36 |
32073798 | [Androgen receptor inhibitors in prostate cancer: new drugs, but for which patient?] | 2019 Nov 28 |
1 |
| 37 |
28851578 | Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). | 2018 Jan |
10 |
| 38 |
30197098 | Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. | 2018 Oct |
2 |
| 39 |
28490267 | Darolutamide (ODM-201) for the treatment of prostate cancer. | 2017 Jun |
2 |
| 40 |
26137992 | Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. | 2015 Jul 3 |
5 |
| 41 |
26313416 | ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. | 2015 |
1 |
| 42 |
24974051 | Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. | 2014 Aug |
4 |